Prognostic Models and Signatures in Retroperitoneal Sarcoma
RNA-seq (gene expression) · human · 119 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Soft tissue sarcomaThis series is part of our curated briefing on it.
- Samples
- 119 samples: 11 conditions, mostly with about 8 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS)Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE296413_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1259244 and SRA study SRP583275. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 119 samples.
How we read this: 11 replicated groups read from 119 sample titles; they account for 119 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8969948 KH16 KH
- GSM8969949 KH20 KH
- GSM8969950 KH22 KH
- GSM8969951 KH24 KH
- GSM8969952 KH46 KH
- GSM8969953 KH49 KH
- GSM8969954 KH52 KH
- GSM8969955 KH55 KH
- GSM8969956 KH58 KH
- GSM8969957 KH76 KH
- GSM8969958 KH79 KH
- GSM8969959 KH82 KH
- GSM8969960 KJ11 KJ
- GSM8969961 KJ14 KJ
- GSM8969962 KJ32 KJ
- GSM8969963 KJ34 KJ
- GSM8969964 KJ36 KJ
- GSM8969965 KJ38 KJ
- GSM8969966 KJ40 KJ
- GSM8969967 KJ42 KJ
- GSM8969968 KJ44 KJ
- GSM8969969 KJ62 KJ
- GSM8969970 KJ64 KJ
- GSM8969971 KJ66 KJ
- GSM8969972 KJ68 KJ
- GSM8969973 KJ70 KJ
- GSM8969974 KQ16 KQ
- GSM8969975 KQ19 KQ
- GSM8969976 KQ36 KQ
- GSM8969977 KQ39 KQ
- GSM8969978 KQ41 KQ
- GSM8969979 KQ45 KQ
- GSM8969980 KQ47 KQ
- GSM8969981 KQ49 KQ
- GSM8969982 KQ67 KQ
- GSM8969983 KQ73 KQ
- GSM8969984 KQ76 KQ
- GSM8969985 KQ78 KQ
- GSM8969986 KQ80 KQ
- GSM8969987 KQ97 KQ
+ 79 more — browse all 119 samples with per-sample file links →
- GSE312030 Combined inhibition of HRAS and MEK induces tumor regression and restores myogenic differentiation in HRAS-mutant rhabdomyosarcoma 159 samples same disease briefing · shares sarcoma
- GSE300974 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [RNA-seq] 30 samples same disease briefing · shares sarcoma
- GSE314949 RNA Seq of rhabdomyosarcoma cells with sgRNA targeting oncofusion interacting proteins 30 samples same disease briefing · shares sarcoma
- GSE279954 mRNA/sRNA Co-Sequencing Reveals Multiple New Targeted Therapy Candidates in Rhabdomyosarcoma 26 samples same disease briefing · shares sarcoma
- GSE287694 Integration of whole genome sequencing analysis with unique patient-derived models reveals clinically relevant drug targets in TFCP2 fusion-defined intraosseous rhabdomyosarcoma 2 samples same disease briefing · shares sarcoma
- GSE292872 FANCM is Required for the PAX3::FOXO1-Driven Oncogenic Program in Rhabdomyosarcoma [RNA-Seq] 21 samples same disease briefing · shares sarcoma
- GSE144190 Systematic profiling of synovial sarcoma transcriptome 20 samples same disease briefing · shares sarcoma
- GSE202614 TLE3 function in rhabdomyosarcoma tumor xenografts. 20 samples same disease briefing · shares sarcoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.